Cargando…

Quality of patient‐reported outcomes in oncology clinical trials using immune checkpoint inhibitors: A systematic review

BACKGROUND: There are limited data regarding the quality of patient‐reported outcome (PRO) data in immune checkpoint inhibitor (ICI) clinical trial publications. METHODS: A systematic search of citations from various databases was conducted to identify prospective clinical trials involving ICI in ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malone, Eoghan, Barua, Reeta, Meti, Nicholas, Li, Xuan, Fazelzad, Rouhi, Hansen, Aaron R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2021
Materias:	Clinical Cancer Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8335827/ https://www.ncbi.nlm.nih.gov/pubmed/34184416 http://dx.doi.org/10.1002/cam4.4086

Ejemplares similares

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
por: Meti, Nicholas, et al.
Publicado: (2018)

Immune checkpoint inhibitor‐associated pituitary‐adrenal dysfunction: A systematic review and meta‐analysis
por: Lu, Jingli, et al.
Publicado: (2019)

Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer
por: Sivapiragasam, Abirami, et al.
Publicado: (2020)

Infectious complications of immune checkpoint inhibitors in solid organ malignancies
por: Ross, Justine Abella, et al.
Publicado: (2021)

Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer
por: Shao, Jun, et al.
Publicado: (2020)

Immune checkpoint inhibitor-associated celiac disease
por: Badran, Yousef R, et al.
Publicado: (2020)

Current progress of immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma
por: Yin, Xiaoqiang, et al.
Publicado: (2022)

Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors
por: Kelleher, Thomas, et al.
Publicado: (2021)

Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists
por: Illouz, Frédéric, et al.
Publicado: (2017)

Endocrine‐related adverse events associated with immune‐checkpoint inhibitors in patients with melanoma
por: Kassi, Eva, et al.
Publicado: (2019)

Recognizing encephalopathy in immune checkpoint inhibitor therapy: A single‐center experience
por: Wei, Danmeng, et al.
Publicado: (2021)

Electrocardiographic features of immune checkpoint inhibitor associated myocarditis
por: Zlotoff, Daniel A, et al.
Publicado: (2021)

Pericardial disease in patients treated with immune checkpoint inhibitors
por: Gong, Jingyi, et al.
Publicado: (2021)

Preexisting immune‐mediated inflammatory disease is associated with improved survival and increased toxicity in melanoma patients who receive immune checkpoint inhibitors
por: Gulati, Nicholas, et al.
Publicado: (2021)

Efficacy of immune‐checkpoint inhibitors in metastatic gastric or gastroesophageal junction adenocarcinoma by patient subgroups: A systematic review and meta‐analysis
por: Kundel, Yulia, et al.
Publicado: (2020)

A real‐world data of Immune checkpoint inhibitors in solid tumors from India
por: Noronha, Vanita, et al.
Publicado: (2021)

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
por: Krebs, Franziska K., et al.
Publicado: (2021)

Semen and serum platinum levels in cisplatin‐treated survivors of germ cell cancer
por: Malone, Eoghan R., et al.
Publicado: (2021)

Cancer patients’ experiences with immune checkpoint modulators: A qualitative study
por: Ala‐Leppilampi, Kari, et al.
Publicado: (2020)

Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis
por: Durbin, Sienna M, et al.
Publicado: (2020)

Host response to immune checkpoint inhibitors contributes to tumor aggressiveness
por: Khononov, Irina, et al.
Publicado: (2021)

Acute kidney injury in patients treated with immune checkpoint inhibitors
por: Gupta, Shruti, et al.
Publicado: (2021)

Novel risk group stratification for metastatic urothelial cancer patients treated with immune checkpoint inhibitors
por: Shabto, Julie M., et al.
Publicado: (2020)

Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors
por: Sander, Michael S., et al.
Publicado: (2021)

COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis
por: Ruiz, Juan Ignacio, et al.
Publicado: (2023)

Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis
por: Cautela, Jennifer, et al.
Publicado: (2020)

Activated osteoarthritis following immune checkpoint inhibitor treatment: an observational study
por: Reid, Pankti, et al.
Publicado: (2021)

Prognosis of immune checkpoint inhibitors-induced myocarditis: a case series
por: Coustal, Cyrille, et al.
Publicado: (2023)

Impact of immune checkpoint inhibitors on atherosclerosis progression in patients with lung cancer
por: Drobni, Zsofia Dora, et al.
Publicado: (2023)

Clinical characteristics and management of immune checkpoint inhibitor‐related pneumonitis: A single‐institution retrospective study
por: Wang, Hanping, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases
por: Schlam, Ilana, et al.
Publicado: (2022)

Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events
por: Coukos, Alexander, et al.
Publicado: (2022)

Application of Value Framework to Phase III Trials of Immune Checkpoint Inhibitors in Esophageal and Gastric Cancer
por: Thawani, Rajat, et al.
Publicado: (2023)

Associations between safety, tolerability, and toxicity and the reporting of health‐related quality of life in phase III randomized trials in common solid tumors
por: Saleh, Ramy R., et al.
Publicado: (2020)

Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors
por: Mamoor, Maha, et al.
Publicado: (2020)

Retrospective efficacy analysis of immune checkpoint inhibitors in patients with EGFR‐mutated non‐small cell lung cancer
por: Yamada, Tadaaki, et al.
Publicado: (2019)

Integrated genomic analysis identifies a genetic mutation model predicting response to immune checkpoint inhibitors in melanoma
por: Jiang, Junjie, et al.
Publicado: (2020)

Association of PTPRT mutations with immune checkpoint inhibitors response and outcome in melanoma and non‐small cell lung cancer
por: Zhang, Wenjing, et al.
Publicado: (2021)

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
por: Mooradian, Meghan J, et al.
Publicado: (2020)

Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors
por: Dolladille, Charles, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_epk7i9kajs5km1uegaren6pchr